References
- Ackerman, T. 2015. For pioneering immunotherapy researcher, the work is far from over. Houston Chronicle. Accessed November 9, 2018. https://www.houstonchronicle.com/news/houston-texas/houston/article/For-pioneering-immunotherapy-researcher-the-work-6728734.php.
- Agata, Y., A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. International Immunology 8 (5):765–72.
- Allison, J. P., A. A. Hurwitz, and D. R. Leach. 1995. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Current Opinion in Immunology 7 (5):682–86. doi:10.1016/0952-7915(95)80077-8.
- Allison, J. P., B. W. McIntyre, and D. Bloch. 1982. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. The Journal of Immunology 129 (5):2293–300.
- American Cancer Society. 2018. Cancer facts & figures 2018. Atlanta, GA: American Cancer Society.
- American Cancer Society. Immune checkpoint inhibitors to treat cancer. Last Modified July 23, 2018. Accessed October 30, 2018. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html.
- American Cancer Society. Treatment types. Accessed October 17, 2018. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types.html.
- Baumgarten, A., and M. J. Polley. 2018. Immunology. AccessScience. doi:10.1036/1097-8542.338700.
- Brahmer, J. R., S. S. Tykodi, L. Q. M. Chow, W.-J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine 366 (26):2455–65. doi:10.1056/NEJMoa1200694.
- Brunet, J.-F., F. Denizot, M.-F. Luciani, M. Roux-Dosseto, M. Suzan, M.-G. Mattei, and P. Golstein. 1987. A new member of the immunoglobulin superfamily – CTLA-4. Nature 328 (6127):267–70. doi:10.1038/328267a0.
- Cancer Research Institute. Immunotherapy fact of the day #20. Accessed November 4, 2018a. https://www.cancerresearch.org/join-the-cause/cancer-immunotherapy-month/30-facts/20.
- Cancer Research Institute. James P. Allison, Ph.D.. Accessed November 12, 2018b. https://www.cancerresearch.org/immunotherapy/stories/scientists/james-p-allison-phd.
- Cancer Research Institute. James P. Allison, Ph.D., su2c-cri cancer immunology dream team investigator. Accessed November 4, 2018c. https://www.cancerresearch.org/scientists/cri-funding-directory/james-p-allison,-ph-d.
- Cancer Research Institute. William B. Coley award. Accessed October 23, 2018d. https://www.cancerresearch.org/about-cri/hall-of-cancer-heroes/william-b-coley-award.
- Carson-DeWitt, R., T. G. Odle, M. Oberleitner, and L. Mertz. 2013. Cancer. In The gale encyclopedia of public health, ed. L. J. Fundukian, 132–40. Detroit, MI: Gale.
- Cavallo, J. 2014. Immunotherapy research of James P. Allison, PhD, has led to a paradigm shift in the treatment of cancer. The ASCO Post. Harborside Press.
- Clark, D. A. 2014. Cytokine. AccessScience. doi: 10.1036/1097-8542.757263.
- Coley, W. B. 1893. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. The American Journal of the Medical Sciences 105 (6):487–512. doi:10.1097/00000441-189305000-00001.
- Coley, W. B. 1910. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus). Proceedings of the Royal Society of Medicine 3 (Surgical Section), 1–48.
- Cornwall, C. 2016. Battling melanoma: One couple’s struggle from diagnosis to cure. Lanham, MD: Rowman & Littlefield.
- Egen, J. G., M. S. Kuhns, and J. P. Allison. 2002. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nature Immunology 3 (7):611–18. doi:10.1038/ni0702-611.
- Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, and M. C. Byrne. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. Journal of Experimental Medicine 192 (7):1027–34.
- Goldsby, R. A., T. J. Kindt, and B. A. Osborne. 2000. T-cell receptor. In Kuby immunology, ed. N. Folchetti, 215–17. New York: W.H. Freeman.
- Graeber, C. 2018. Meet the carousing, harmonica-playing texan who just won a Nobel for his cancer breakthrough. Wired. Condé Nast.
- Gribben, J. G., G. J. Freeman, V. A. Boussiotis, P. Rennert, C. L. Jellis, E. Greenfield, M. Barber, V. A. Restivo, X. Ke, and G. S. Gray. 1995. CTLA-4 mediates antigen-specific apoptosis of human T cells. Proceedings of the National Academy of Sciences 92 (3):811–15. doi:10.1073/pnas.92.3.811.
- Gross, J. A., T. St John, and J. P. Allison. 1990. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. The Journal of Immunology 144 (8):3201–10.
- Hamanishi, J., M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, et al. 2007. Programmed cell death 1 Ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 104 (9):3360–65. doi:10.1073/pnas.0611533104.
- Honjo, T. 2003. Fascinated by the mechanism of immunity-engaging all things fully and with vigor. Biohistory 37. Accessed November 13, 2018.
- Honjo, T. 2012. Robert Koch prize acceptance speech. The Robert Koch Foundation. JT Biohistory Research Hall: Osaka Japan. Accessed November 2, 2018. https://www.robert-koch-stiftung.de/index.php?article_id=108&clang=1.
- Honjo, T. 2018. Interviewed by Adam Smith: Nobel media AB. Accessed November 14, 2018. https://www.nobelprize.org/prizes/medicine/2018/honjo/interview/
- Honjo, T. Tasuku honjo curriculum vitae. Department of Immunology and Genomic Medicine Kyoto University. Accessed November 13, 2018a. http://www2.mfour.med.kyoto-u.ac.jp/en/E_CV.html.
- Howard, T. A., J. M. Rochelle, and M. F. Seldin. 1991. CD28 and CTLA-4, 2 related members of the Ig supergene family, are tightly linked on proximal mouse chromosome-1. Immunogenetics 33 (1):74–76.
- Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal 11 (11):3887–95.
- Kärre, K. 2018. These scientists have figured out how to block the brakes of the immune system. In NobelPrize.org, ed. L. Fredholm. Nobel Media AB 2018. Retrieved from https://www.nobelprize.org/prizes/medicine/2018/prize-announcement/
- Keegan, P. 2018. Bla 125377/s-096. Silver Spring, MD: Food and Drug Administration.
- Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T-cells to stimulation. Journal of Experimental Medicine 182 (2):459–65. doi:10.1084/jem.182.2.459.
- Kyoto University. Tasuku Honjo. Accessed November 13, 2018. http://www.kyoto-u.ac.jp/static/en/research/forefronts/archives/honjo.html.
- Lafage-Pochitaloff, M., R. Costello, D. Couez, J. Simonetti, P. Mannoni, C. Mawas, and D. Olive. 1990. Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome-2 at bands q33-q34. Immunogenetics 31 (3):198–201.
- Lamichhane, P., N. P. Amin, M. Agarwal, and N. Lamichhane. 2018. Checkpoint inhibition: Will combination with radiotherapy and nanoparticle-mediated delivery improve efficacy? Medicines (Basel) 5 (4). doi: 10.3390/medicines5040114.
- Latchman, Y., C. R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A. J. Long, J. A. Brown, R. Nunes, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology 2 (3):261–68. doi:10.1038/85330.
- Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (5256):1734–36. doi:10.1126/science.271.5256.1734.
- Linsley, P. S., J. L. Greene, P. Tan, J. Bradshaw, J. A. Ledbetter, C. Anasetti, and N. K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. The Journal of Experimental Medicine 176 (6):1595. doi:10.1084/jem.176.6.1595.
- Loftus, D. J. 2014. Cellular Immunology. AccessScience. doi: 10.1036/1097-8542.118100.
- Lopez, M. 2018. Alice native Dr. James Allison awarded 2018 Nobel Prize in Physiology or Medicine. Caller Times. Accessed November 9, 2018.
- McCarthy, E. F. 2006. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. The Iowa Orthopaedic Journal 26:154–58.
- MD Anderson Cancer Center. James P. Allison, Ph.D.. Accessed November 9, 2018a. https://faculty.mdanderson.org/profiles/james_allison.html.
- MD Anderson Cancer Center. 2018b. MD Anderson immunologist Jim Allison awarded Nobel Prize. Texas: University of Texas. Accessed October 1, 2018 https://www.mdanderson.org/newsroom/2018/10/md-anderson-immunologist-jim-allison-awarded-nobel-prize.html
- National Cancer Institute. Cancer types. Accessed October 17, 2018. https://www.cancer.gov/types.
- National Cancer Institute Dictionary of Cancer Terms, ND. Cancer. Bethesda, MD: National Institutes of Health.
- National Cancer Institute Dictionary of Cancer Terms, ND. Immune checkpoint inhibitor. Bethesda, MD: National Institutes of Health.
- National Center for Health Statistics. Cancer. Center for Disease Control and Prevention. Last Modified May 3, 2017. Accessed October 17, 2018. https://www.cdc.gov/nchs/fastats/cancer.htm.
- National Institutes of Health. 2016. Blue ribbon panel announced to help guide vice president Biden’s national cancer moonshot initiative. Last Modified April 4, 2016. Accessed November 9, 2018. https://www.nih.gov/news-events/news-releases/blue-ribbon-panel-announced-help-guide-vice-president-bidens-national-cancer-moonshot-initiative.
- Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an itim motif-carrying immunoreceptor. Immunity 11 (2):141–51.
- Nishimura, H., N. Minato, T. Nakano, and T. Honjo. 1998. Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses. International Immunology 10 (10):1563–72.
- Nishimura, H., Y. Agata, A. Kawasaki, M. Sato, S. Imamura, N. Minato, H. Yagita, T. Nakano, and T. Honjo. 1996. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. International Immunology 8 (5):773–80.
- NobelPrize.org. Alfred Nobel’s will. Nobel Media AB 2018. Accessed November 7, 2018. https://www.nobelprize.org/alfred-nobel/alfred-nobels-will-2/.
- NobelPrize.org. The Nobel Prize in Physiology or Medicine. Nobel AB. Accessed October 17, 2018. https://www.nobelprize.org/prizes/medicine/.
- NobelPrize.org. 2018a. Announcement of the 2018 Nobel Prize in Physiology or Medicine. Stockholm, Sweden: Nobel Media AB 2018.
- NobelPrize.org. 2018b. Press release. Stockholm, Sweden: Nobel Media AB 2018.
- O’Day, S. J., M. Maio, V. Chiarion-Sileni, T. F. Gajewski, H. Pehamberger, I. N. Bondarenko, P. J. Queirolo, L. Lundgren, S. Mikhailov, L. Roman, et al. 2010. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Annals of Oncology 21 (8):1712–17. doi:10.1093/annonc/mdq013.
- Park, A. 2017. James Allison. Time. http://time.com/collection/2017-time-100/4742750/james-allison/
- Piore, A. 2017. James Allison has unfinished business with cancer. MIT Technology Review.
- Schmid, P., S. Adams, H. S. Rugo, A. Schneeweiss, C. H. Barrios, H. Iwata, V. Diéras, R. Hegg, S.-A. Im, G. S. Wright, et al. 2018. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine. doi:10.1056/NEJMoa1809615.
- SEER*Rx. Ipilimumab. National Cancer Institute. Accessed October 17, 2018a. https://seer.cancer.gov/seertools/seerrx/rx/53c44afc102c1290262dc528/?regimen_field%3Dscore%26rx_type%3Ddrug%26drug_offset%3D0%26regimen_offset%3D0%26q%3DYervoy%26limit%3D25%26drug_field%3Dscore%26search_mode%3D%26drug_direction%3DUP%26regimen_direction%3DUP%26mode%3D.
- SEER*Rx. Opdivo. National Cancer Institute. Accessed October 17, 2018b. https://seer.cancer.gov/seertools/seerrx/rx/53c44afc102c1290262dc528/?regimen_field%3Dscore%26rx_type%3Ddrug%26drug_offset%3D0%26regimen_offset%3D0%26q%3DYervoy%26limit%3D25%26drug_field%3Dscore%26search_mode%3D%26drug_direction%3DUP%26regimen_direction%3DUP%26mode%3D.
- Segaliny, A. I., G. Li, L. Kong, C. Ren, X. Chen, J. K. Wang, D. Baltimore, G. Wu, and W. Zhao. 2018. Functional TCR T cell screening using single-cell droplet microfluidics. Lab on a Chip. doi:10.1039/C8LC00818C.
- Tang, J., A. Shalabi, and V. M. Hubbard-Lucey. 2018. Comprehensive analysis of the clinical immuno-oncology landscape. Annals of Oncology 29 (1):84–91. doi:10.1093/annonc/mdx755.
- Time Magazine. 2017. The 100 most influential people. Time.
- Townsend, S. E., and J. P. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T-cells by B7-transfected melanoma-cells. Science 259 (5093):368–70. doi:10.1126/science.7678351.
- UCI News. 2018. New immunotherapy technique can specifically target tumor cells, UCI study reports. University of California, Irvine. Last Modified November 6, 2018. Accessed November 7, 2018. https://news.uci.edu/2018/11/06/new-immunotherapy-technique-can-specifically-target-tumor-cells-uci-study-reports/.
- Vibhakar, R., G. Juan, F. Traganos, Z. Darzynkiewicz, and L. R. Finger. 1997. Activation-induced expression of human Programmed Death-1 gene in T-lymphocytes. Experimental Cell Research 232 (1):25–28. doi:10.1006/excr.1997.3493.
- Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (5):405–13.
- Wang, D. Y., J.-E. Salem, J. V. Cohen, S. Chandra, C. Menzer, F. Ye, S. Zhao, S. Das, K. Berkermann, L. Ha, et al. 2018. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncology. doi:10.1001/jamaoncol.2018.3923.
- Wei, S., C. Colm, R. Duffy, and J. P. Allison. 2018. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery 8 (9):1069–86. doi:10.1158/2159-8290.Cd-18-0367.
- World Health Organization. Cancer. Last Modified September 12, 2018. Accessed October 17, 2018. http://www.who.int/news-room/fact-sheets/detail/cancer.